JRCT ID: jRCTs052210163
Registered date:01/02/2022
FRAT Study
Basic Information
Recruitment status | Recruiting |
---|---|
Health condition(s) or Problem(s) studied | Cerebrovascular disease |
Date of first enrollment | 14/03/2022 |
Target sample size | 20 |
Countries of recruitment | |
Study type | Interventional |
Intervention(s) | Rehabilitation using IVES+ for 20 minutes per day |
Outcome(s)
Primary Outcome | Change in the amount of upper limb Fugl-Meyer Assessment(FMA)with respect to pre-intervention value at week 2 |
---|---|
Secondary Outcome | 1.Changes in the amount of Functional Independence Measure(FIM)with respect to pre-intervention value at the 2nd and 4th weeks 2.Changes in the amount of upper limb BRS with respect to pre-intervention value at the 2nd and 4th weeks 3.Changes in the amount of upper limb FMA with respect to pre-intervention value at the 1st, 3rd, and 4th weeks 4.Changes in the amount of Barthel Index(BI)with respect to pre-intervention value at the 2nd and 4th weeks 5.Changes in grip strength with respect to the pre-intervention value at the 1st, 2nd, 3rd, and 4th weeks 6.Changes in the amount of upper limb Manual Muscle Test(MMT)with respect to pre-intervention value at the 1st, 2nd, 3rd, and 4th weeks |
Key inclusion & exclusion criteria
Age minimum | >= 20age old |
---|---|
Age maximum | Not applicable |
Gender | Both |
Include criteria | 1. Within 1 month of cerebrovascular event (cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage) 2. With upper limb Brunnstrom stage(BRS)2-4 3. Who are 20 years of age or older at the time of obtaining informed consent 4. Whose consent to participate in this clinical study and the informed consent of the patient have has been obtained in writing |
Exclude criteria | 1. Received treatments, such as botulinum therapy, repeated transcranial magnetic stimulation, transcranial direct current stimulation within 90 days of obtaining consent 2. With a history of surgery(including device therapy)or intravenous t-PA for cerebrovascular event (cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage) 3.Cognitive decline(Mini-Mental State Examination(MMSE)is 21 or less) 4.Severe skin symptoms on the affected upper limb 5.Have a history of epileptic seizures 6.With a history of substance abuse or addiction(including alcoholism)at the time of enrollment and within the past year, or patients with complications 7.Using an implantable cardiac stimulator such as a cardiac pacemaker or an implantable assisted heart 8.Using deep brain stimulation 9.With metal(excluding titanium products)implanted in the affected upper limb 10.Who are pregnant or may become pregnant 11.Who are judged by doctors to be inappropriate as research subjects |
Related Information
Primary Sponsor | Kobayashi Yasuyo |
---|---|
Secondary Sponsor | OG Wellness |
Source(s) of Monetary Support | Nara Medical University |
Secondary ID(s) |
Contact
Public contact | |
Name | Yasuyo Kobayashi |
Address | 840 Shijo-cho Kashihara-shi Nara,Japan Nara Japan 634-8522 |
Telephone | +81-744-22-3051 |
tyasuyo@naramed-u.ac.jp | |
Affiliation | Nara Medical University Hospital |
Scientific contact | |
Name | Yasuyo Kobayashi |
Address | 840 Shijo-cho Kashihara-shi Nara,Japan Nara Japan 634-8522 |
Telephone | +81-744-22-3051 |
tyasuyo@naramed-u.ac.jp | |
Affiliation | Nara Medical University Hospital |